[18F]F-AraG Injection for Non-small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-small Cell Lung Cancer[18F]F-AraG Injection - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will use a radioactive compound to detect changes in a patient's cancer immunotherapy response.

Eligible Conditions
  • Non-small Cell Lung Cancer

Treatment Effectiveness

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 5 years

5 years
Correlation between [18F]F-AraG uptake and percent pathologic response as assessed by the Spearman correlation coefficient
At the time of surgery
Percent pathologic response at the time of surgery
Day 14
Percent Change in uptake of [18F]F-AraG before and after one dose of anti-PD-L1

Trial Safety

Trial Design

1 Treatment Group

[18F]F-AraG
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: [18F]F-AraG Injection · No Placebo Group · Phase 1

[18F]F-AraG
Drug
Experimental Group · 1 Intervention: [18F]F-AraG Injection · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 5 years

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
536 Previous Clinical Trials
31,245 Total Patients Enrolled
CellSight Technologies, Inc.Industry Sponsor
15 Previous Clinical Trials
277 Total Patients Enrolled
2 Trials studying Non-small Cell Lung Cancer
2 Patients Enrolled for Non-small Cell Lung Cancer
Stand Up To CancerOTHER
45 Previous Clinical Trials
33,282 Total Patients Enrolled
Martin Pomper, M.D., Ph.D.Principal InvestigatorJohns Hopkins University

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Someone who is 18 years or older and is able to make an informed decision can provide consent.
, exempt from the IDE requirements, or off-label use of an approved PD-1/PD-L1 inhibitor People with stage I, II, or III cancer that has not spread to other parts of the body and who plan to have surgery to remove the cancer will receive neoadjuvant therapy with a PD-1 or PD-L1 inhibitor
The patient must have a Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at the time of enrollment.
Females of childbearing potential will have a negative serum pregnancy test within 10 days of the PET study.